Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer

Brian Bierie, Christine H. Chung, Joel S. Parker, Daniel G. Stover, Nikki Cheng, Anna Chytil, Mary Aakre, Yu Shyr, Harold L. Moses

Research output: Contribution to journalArticle

Abstract

In human breast cancer, loss of carcinoma cell-specific response to TGF-β signaling has been linked to poor patient prognosis. However, the mechanisms through which TGF-β regulates these processes remain largely unknown. In an effort to address this issue, we have now identified gene expression signatures associated with the TGF-β signaling pathway in human mammary carcinoma cells. The results strongly suggest that TGF-β signaling mediates intrinsic, stromal-epithelial, and host-tumor interactions during breast cancer progression, at least in part, by regulating basal and oncostatin M-induced CXCL1, CXCL5, and CCL20 chemokine expression. To determine the clinical relevance of our results, we queried our TGF-β-associated gene expression signatures in 4 human breast cancer data sets containing a total of 1,319 gene expression profiles and associated clinical outcome data. The signature representing complete abrogation of TGF-β signaling correlated with reduced relapse-free survival in all patients; however, the strongest association was observed in patients with estrogen receptor-positive (ER-positive) tumors, specifically within the luminal A subtype. Together, the results suggest that assessment of TGF-β signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer.

Original languageEnglish (US)
Pages (from-to)1571-1582
Number of pages12
JournalJournal of Clinical Investigation
Volume119
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Chemokines
Breast Neoplasms
Transcriptome
Estrogen Receptors
Chemokine CXCL5
Chemokine CCL20
Chemokine CXCL1
Oncostatin M
Neoplasms
Carcinoma
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bierie, B., Chung, C. H., Parker, J. S., Stover, D. G., Cheng, N., Chytil, A., ... Moses, H. L. (2009). Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. Journal of Clinical Investigation, 119(6), 1571-1582. https://doi.org/10.1172/JCI37480

Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. / Bierie, Brian; Chung, Christine H.; Parker, Joel S.; Stover, Daniel G.; Cheng, Nikki; Chytil, Anna; Aakre, Mary; Shyr, Yu; Moses, Harold L.

In: Journal of Clinical Investigation, Vol. 119, No. 6, 01.06.2009, p. 1571-1582.

Research output: Contribution to journalArticle

Bierie, B, Chung, CH, Parker, JS, Stover, DG, Cheng, N, Chytil, A, Aakre, M, Shyr, Y & Moses, HL 2009, 'Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer', Journal of Clinical Investigation, vol. 119, no. 6, pp. 1571-1582. https://doi.org/10.1172/JCI37480
Bierie, Brian ; Chung, Christine H. ; Parker, Joel S. ; Stover, Daniel G. ; Cheng, Nikki ; Chytil, Anna ; Aakre, Mary ; Shyr, Yu ; Moses, Harold L. / Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 6. pp. 1571-1582.
@article{ecfc36b2371e4b2ebff29cc84ebf00aa,
title = "Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer",
abstract = "In human breast cancer, loss of carcinoma cell-specific response to TGF-β signaling has been linked to poor patient prognosis. However, the mechanisms through which TGF-β regulates these processes remain largely unknown. In an effort to address this issue, we have now identified gene expression signatures associated with the TGF-β signaling pathway in human mammary carcinoma cells. The results strongly suggest that TGF-β signaling mediates intrinsic, stromal-epithelial, and host-tumor interactions during breast cancer progression, at least in part, by regulating basal and oncostatin M-induced CXCL1, CXCL5, and CCL20 chemokine expression. To determine the clinical relevance of our results, we queried our TGF-β-associated gene expression signatures in 4 human breast cancer data sets containing a total of 1,319 gene expression profiles and associated clinical outcome data. The signature representing complete abrogation of TGF-β signaling correlated with reduced relapse-free survival in all patients; however, the strongest association was observed in patients with estrogen receptor-positive (ER-positive) tumors, specifically within the luminal A subtype. Together, the results suggest that assessment of TGF-β signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer.",
author = "Brian Bierie and Chung, {Christine H.} and Parker, {Joel S.} and Stover, {Daniel G.} and Nikki Cheng and Anna Chytil and Mary Aakre and Yu Shyr and Moses, {Harold L.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1172/JCI37480",
language = "English (US)",
volume = "119",
pages = "1571--1582",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer

AU - Bierie, Brian

AU - Chung, Christine H.

AU - Parker, Joel S.

AU - Stover, Daniel G.

AU - Cheng, Nikki

AU - Chytil, Anna

AU - Aakre, Mary

AU - Shyr, Yu

AU - Moses, Harold L.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - In human breast cancer, loss of carcinoma cell-specific response to TGF-β signaling has been linked to poor patient prognosis. However, the mechanisms through which TGF-β regulates these processes remain largely unknown. In an effort to address this issue, we have now identified gene expression signatures associated with the TGF-β signaling pathway in human mammary carcinoma cells. The results strongly suggest that TGF-β signaling mediates intrinsic, stromal-epithelial, and host-tumor interactions during breast cancer progression, at least in part, by regulating basal and oncostatin M-induced CXCL1, CXCL5, and CCL20 chemokine expression. To determine the clinical relevance of our results, we queried our TGF-β-associated gene expression signatures in 4 human breast cancer data sets containing a total of 1,319 gene expression profiles and associated clinical outcome data. The signature representing complete abrogation of TGF-β signaling correlated with reduced relapse-free survival in all patients; however, the strongest association was observed in patients with estrogen receptor-positive (ER-positive) tumors, specifically within the luminal A subtype. Together, the results suggest that assessment of TGF-β signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer.

AB - In human breast cancer, loss of carcinoma cell-specific response to TGF-β signaling has been linked to poor patient prognosis. However, the mechanisms through which TGF-β regulates these processes remain largely unknown. In an effort to address this issue, we have now identified gene expression signatures associated with the TGF-β signaling pathway in human mammary carcinoma cells. The results strongly suggest that TGF-β signaling mediates intrinsic, stromal-epithelial, and host-tumor interactions during breast cancer progression, at least in part, by regulating basal and oncostatin M-induced CXCL1, CXCL5, and CCL20 chemokine expression. To determine the clinical relevance of our results, we queried our TGF-β-associated gene expression signatures in 4 human breast cancer data sets containing a total of 1,319 gene expression profiles and associated clinical outcome data. The signature representing complete abrogation of TGF-β signaling correlated with reduced relapse-free survival in all patients; however, the strongest association was observed in patients with estrogen receptor-positive (ER-positive) tumors, specifically within the luminal A subtype. Together, the results suggest that assessment of TGF-β signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=67651005826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651005826&partnerID=8YFLogxK

U2 - 10.1172/JCI37480

DO - 10.1172/JCI37480

M3 - Article

C2 - 19451693

AN - SCOPUS:67651005826

VL - 119

SP - 1571

EP - 1582

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -